Symbols / DVAX $15.50 +0.00%
DVAX Chart
About
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 1.82B |
| Enterprise Value | 1.46B | Income | -43.40M | Sales | 330.51M |
| Book/sh | 4.55 | Cash/sh | 5.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 405 | IPO | Feb 19, 2004 |
| P/E | — | Forward P/E | 46.97 | PEG | — |
| P/S | 5.51 | P/B | 3.41 | P/C | — |
| EV/EBITDA | 60.37 | EV/Sales | 4.42 | Quick Ratio | 6.78 |
| Current Ratio | 7.62 | Debt/Eq | 54.15 | LT Debt/Eq | — |
| EPS (ttm) | -0.37 | EPS next Y | 0.33 | EPS Growth | 69.30% |
| Revenue Growth | 17.70% | Earnings | 2025-11-05 16:00 | ROA | 1.20% |
| ROE | -7.14% | ROIC | — | Gross Margin | 61.60% |
| Oper. Margin | 24.77% | Profit Margin | -13.13% | Shs Outstand | 113.68M |
| Shs Float | 100.34M | Short Float | 13.19% | Short Ratio | 2.81 |
| Short Interest | — | 52W High | 15.73 | 52W Low | 0.00 |
| Beta | 0.93 | Avg Volume | 3.22M | Volume | 0.00 |
| Target Price | $16.00 | Recom | Strong_buy | Prev Close | $15.50 |
| Price | $15.50 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.00
Mean price target
2. Current target
$15.50
Latest analyst target
3. DCF / Fair value
$8.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.50
Low
$16.00
High
$16.00
Mean
$16.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-24 | down | William Blair | Outperform → Market Perform | — |
| 2025-08-22 | reit | JMP Securities | Market Outperform → Market Outperform | $32 |
| 2025-08-08 | main | JMP Securities | Market Outperform → Market Outperform | $32 |
| 2025-05-07 | main | JMP Securities | Market Outperform → Market Outperform | $31 |
| 2025-04-17 | main | Goldman Sachs | Sell → Sell | $10 |
| 2025-02-21 | main | Citizens Capital Markets | Market Outperform → Market Outperform | $33 |
| 2025-02-21 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-02-11 | down | Goldman Sachs | Neutral → Sell | $12 |
| 2025-01-14 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-10-15 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-08-08 | main | Goldman Sachs | Neutral → Neutral | $15 |
| 2024-08-07 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2024-02-01 | init | Goldman Sachs | — → Neutral | $20 |
| 2023-11-03 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2023-11-03 | main | HC Wainwright & Co. | Buy → Buy | $28 |
| 2023-08-04 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
- Market Wrap: Can DVAX stock continue upward trend - Trend Reversal & Reliable Price Action Trade Plans - Naître et grandir Sat, 07 Mar 2026 01
- (DVAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Sat, 07 Mar 2026 09
- Jim Cramer Highlights Sanofi’s Bid for Dynavax - Yahoo Finance Wed, 14 Jan 2026 08
- Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - The Motley Fool Fri, 30 Jan 2026 08
- Dynavax (Nasdaq: DVAX) to Join Evercore Healthcare Conference Fireside Chat on Dec. 2 - Stock Titan Wed, 19 Nov 2025 08
- Dynavax gains on disclosure another bidder interested after deal announced (DVAX:NASDAQ) - Seeking Alpha Mon, 12 Jan 2026 08
- Rhenman & Partners Asset Management Boosts Stake in Dynavax Technologies - National Today Sun, 08 Mar 2026 17
- Sanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting - Investing.com ue, 10 Feb 2026 08
- Why Did Dynavax Stock Surge 38% In Premarket Today? - Stocktwits Wed, 24 Dec 2025 11
- Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - simplywall.st Sat, 08 Nov 2025 08
- Dynavax Stock (+38%): Sanofi Buyout Closes Valuation Gap - Trefis hu, 25 Dec 2025 08
- Stocks making the biggest moves premarket: Nike, Dynavax Technologies, UiPath & more - CNBC Wed, 24 Dec 2025 08
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX) - PR Newswire Mon, 05 Jan 2026 08
- Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group - Yahoo Finance ue, 10 Feb 2026 08
- Why Dynavax Stock Soared Today - The Motley Fool Wed, 24 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 92424 | — | — | Stock Award(Grant) at price 0.00 per share. | SLEBIR JOHN L | General Counsel | — | 2026-02-10 00:00:00 | D |
| 1 | 124224 | — | — | Stock Award(Grant) at price 0.00 per share. | NOVACK DAVID F | President | — | 2026-02-10 00:00:00 | D |
| 2 | 301000 | — | — | Stock Award(Grant) at price 0.00 per share. | SPENCER RYAN | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
| 3 | 88854 | — | — | Stock Award(Grant) at price 0.00 per share. | MACDONALD KELLY | Chief Financial Officer | — | 2026-02-10 00:00:00 | D |
| 4 | 114000 | 1782960.0 | — | Sale at price 15.64 per share. | NOVACK DAVID F | President | — | 2026-01-15 00:00:00 | D |
| 5 | 114000 | 1120280.0 | — | Conversion of Exercise of derivative security at price 6.80 - 10.47 per share. | NOVACK DAVID F | President | — | 2026-01-15 00:00:00 | D |
| 6 | 30000 | 464700.0 | — | Sale at price 15.49 per share. | NOVACK DAVID F | President | — | 2025-12-24 00:00:00 | D |
| 7 | 71408 | 240800.0 | — | Conversion of Exercise of derivative security at price 6.80 - 10.47 per share. | NOVACK DAVID F | President | — | 2025-12-24 00:00:00 | D |
| 8 | 33750 | — | — | Stock Award(Grant) at price 0.00 per share. | SLEBIR JOHN L | General Counsel | — | 2025-12-23 00:00:00 | D |
| 9 | 30808 | nan | — | — | SLEBIR JOHN L | General Counsel | — | 2025-12-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -2.38M | 10.88K | -535.86K |
| TaxRateForCalcs | 0.12 | 0.21 | 0.00 | 0.01 |
| NormalizedEBITDA | 45.70M | 20.98M | 304.90M | 149.34M |
| TotalUnusualItems | 0.00 | -11.31M | 2.80M | -53.59M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -11.31M | 2.80M | -53.59M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 27.31M | -6.39M | 293.16M | 76.71M |
| ReconciledDepreciation | 8.05M | 7.28M | 6.67M | 7.06M |
| ReconciledCostOfRevenue | 49.45M | 50.17M | 262.15M | 173.57M |
| EBITDA | 45.70M | 9.67M | 307.70M | 95.75M |
| EBIT | 37.65M | 2.39M | 301.03M | 88.70M |
| NetInterestIncome | 29.67M | 25.24M | 1.18M | -11.04M |
| InterestExpense | 6.79M | 6.76M | 6.73M | 11.18M |
| InterestIncome | 36.46M | 31.99M | 7.91M | 140.00K |
| NormalizedIncome | 27.31M | 2.55M | 290.37M | 129.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 27.31M | -6.39M | 293.16M | 76.71M |
| TotalExpenses | 281.37M | 258.00M | 440.16M | 305.96M |
| TotalOperatingIncomeAsReported | -4.12M | -37.03M | 283.52M | 134.49M |
| DilutedAverageShares | 133.34M | 128.73M | 150.80M | 133.01M |
| BasicAverageShares | 130.05M | 128.73M | 126.40M | 116.26M |
| DilutedEPS | 0.20 | -0.05 | 1.97 | 0.57 |
| BasicEPS | 0.21 | -0.05 | 2.32 | 0.62 |
| DilutedNIAvailtoComStockholders | 27.31M | -6.39M | 296.40M | 75.69M |
| AverageDilutionEarnings | 0.00 | 0.00 | 3.53M | 3.55M |
| NetIncomeCommonStockholders | 27.31M | -6.39M | 292.87M | 72.14M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 283.00K | 4.57M |
| NetIncome | 27.31M | -6.39M | 293.16M | 76.71M |
| NetIncomeIncludingNoncontrollingInterests | 27.31M | -6.39M | 293.16M | 76.71M |
| NetIncomeContinuousOperations | 27.31M | -6.39M | 293.16M | 76.71M |
| TaxProvision | 3.55M | 2.02M | 1.14M | 808.00K |
| PretaxIncome | 30.86M | -4.37M | 294.30M | 77.52M |
| OtherIncomeExpense | 5.31M | -3.89M | 10.60M | -44.93M |
| OtherNonOperatingIncomeExpenses | 5.31M | 7.42M | 7.80M | 8.66M |
| SpecialIncomeCharges | 0.00 | -11.31M | 1.00M | -4.23M |
| GainOnSaleOfPPE | 0.00 | 1.00M | 1.00M | 1.00M |
| OtherSpecialCharges | 5.23M | |||
| WriteOff | 0.00 | 12.31M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 1.80M | -49.35M | ||
| NetNonOperatingInterestIncomeExpense | 29.67M | 25.24M | 1.18M | -11.04M |
| InterestExpenseNonOperating | 6.79M | 6.76M | 6.73M | 11.18M |
| InterestIncomeNonOperating | 36.46M | 31.99M | 7.91M | 140.00K |
| OperatingIncome | -4.12M | -25.71M | 282.52M | 133.49M |
| OperatingExpense | 231.92M | 207.83M | 178.01M | 132.38M |
| ResearchAndDevelopment | 61.55M | 54.89M | 46.60M | 32.23M |
| SellingGeneralAndAdministration | 170.37M | 152.95M | 131.41M | 100.16M |
| GeneralAndAdministrativeExpense | 170.37M | 152.95M | 131.41M | 100.16M |
| OtherGandA | 64.99M | 59.94M | 55.42M | 42.13M |
| SalariesAndWages | 105.38M | 93.01M | 75.98M | 58.03M |
| GrossProfit | 227.80M | 182.12M | 460.53M | 265.87M |
| CostOfRevenue | 49.45M | 50.17M | 262.15M | 173.57M |
| TotalRevenue | 277.25M | 232.28M | 722.68M | 439.44M |
| OperatingRevenue | 268.43M | 213.29M | 713.64M | 437.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 125.45M | 129.53M | 127.60M | 122.94M |
| ShareIssued | 125.45M | 129.53M | 127.60M | 122.94M |
| NetDebt | 127.97M | 72.42M | 19.57M | |
| TotalDebt | 254.42M | 256.91M | 258.01M | 257.38M |
| TangibleBookValue | 594.85M | 620.00M | 579.01M | 220.25M |
| InvestedCapital | 820.65M | 844.77M | 802.59M | 442.86M |
| WorkingCapital | 770.31M | 796.92M | 766.91M | 416.12M |
| NetTangibleAssets | 594.85M | 620.00M | 579.01M | 220.25M |
| CapitalLeaseObligations | 30.56M | 34.22M | 36.43M | 36.89M |
| CommonStockEquity | 596.80M | 622.07M | 581.01M | 222.37M |
| TotalCapitalization | 820.65M | 844.77M | 802.59M | 442.86M |
| TotalEquityGrossMinorityInterest | 596.80M | 622.07M | 581.01M | 222.37M |
| StockholdersEquity | 596.80M | 622.07M | 581.01M | 222.37M |
| GainsLossesNotAffectingRetainedEarnings | -4.72M | -2.11M | -5.44M | -2.27M |
| OtherEquityAdjustments | -4.72M | -2.11M | -5.44M | |
| RetainedEarnings | -903.27M | -930.58M | -924.20M | -1.22B |
| AdditionalPaidInCapital | 1.50B | 1.55B | 1.51B | 1.44B |
| CapitalStock | 125.00K | 130.00K | 128.00K | 123.00K |
| CommonStock | 125.00K | 130.00K | 128.00K | 123.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 389.46M | 375.02M | 404.84M | 816.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 310.82M | 312.83M | 254.76M | 260.47M |
| OtherNonCurrentLiabilities | 244.00K | 74.00K | 384.00K | 5.66M |
| NonCurrentAccruedExpenses | 60.34M | 60.34M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 250.24M | 252.42M | 254.38M | 254.81M |
| LongTermCapitalLeaseObligation | 26.39M | 29.72M | 32.80M | 34.32M |
| LongTermDebt | 223.85M | 222.70M | 221.58M | 220.49M |
| CurrentLiabilities | 78.63M | 62.20M | 150.07M | 556.40M |
| OtherCurrentLiabilities | 22.00K | 24.00K | 18.03M | |
| CurrentDeferredLiabilities | 0.00 | 349.86M | ||
| CurrentDeferredRevenue | 0.00 | 349.86M | ||
| CurrentDebtAndCapitalLeaseObligation | 4.17M | 4.50M | 3.63M | 2.58M |
| CurrentCapitalLeaseObligation | 4.17M | 4.50M | 3.63M | 2.58M |
| PayablesAndAccruedExpenses | 74.44M | 57.67M | 146.44M | 185.93M |
| CurrentAccruedExpenses | 65.38M | 52.43M | 143.23M | 183.33M |
| Payables | 9.06M | 5.25M | 3.21M | 2.60M |
| AccountsPayable | 9.06M | 5.25M | 3.21M | 2.60M |
| TotalAssets | 986.26M | 997.10M | 985.85M | 1.04B |
| TotalNonCurrentAssets | 137.31M | 137.98M | 68.86M | 66.73M |
| OtherNonCurrentAssets | 74.76M | 74.33M | 3.52M | 3.62M |
| GoodwillAndOtherIntangibleAssets | 1.95M | 2.07M | 2.01M | 2.12M |
| Goodwill | 1.95M | 2.07M | 2.01M | 2.12M |
| NetPPE | 60.61M | 61.58M | 63.34M | 60.98M |
| AccumulatedDepreciation | -34.17M | -31.83M | -27.52M | -25.38M |
| GrossPPE | 94.78M | 93.42M | 90.86M | 86.36M |
| Leases | 36.53M | 37.20M | 28.82M | 27.63M |
| ConstructionInProgress | 10.12M | 5.82M | 11.61M | 9.94M |
| OtherProperties | 39.76M | 42.87M | 43.24M | 40.99M |
| MachineryFurnitureEquipment | 8.36M | 7.53M | 7.18M | 7.80M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 848.94M | 859.12M | 916.99M | 972.52M |
| OtherCurrentAssets | 18.15M | 19.00M | 85.63M | 73.76M |
| PrepaidAssets | 0.00 | 159.66M | ||
| Inventory | 70.05M | 53.29M | 59.45M | 61.34M |
| FinishedGoods | 12.85M | 7.08M | 9.99M | 19.95M |
| WorkInProcess | 14.57M | 18.95M | 23.93M | 14.75M |
| RawMaterials | 42.64M | 27.26M | 25.52M | 26.64M |
| Receivables | 46.91M | 44.53M | 147.51M | 131.82M |
| OtherReceivables | 1.62M | 3.93M | 2.38M | 15.60M |
| AccountsReceivable | 45.28M | 40.61M | 145.13M | 116.22M |
| AllowanceForDoubtfulAccountsReceivable | -12.31M | -12.31M | 0.00 | |
| GrossAccountsReceivable | 57.59M | 52.92M | 145.13M | |
| CashCashEquivalentsAndShortTermInvestments | 713.83M | 742.30M | 624.39M | 545.95M |
| OtherShortTermInvestments | 617.95M | 592.02M | 422.39M | 109.76M |
| CashAndCashEquivalents | 95.88M | 150.28M | 202.00M | 436.19M |
| CashEquivalents | 83.73M | 139.09M | 172.42M | 429.19M |
| CashFinancial | 12.16M | 11.19M | 29.59M | 7.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 60.16M | 96.46M | 55.58M | 326.05M |
| RepurchaseOfCapitalStock | -100.00M | 0.00 | 0.00 | |
| RepaymentOfDebt | 0.00 | 0.00 | -190.19M | |
| IssuanceOfDebt | 0.00 | 0.00 | 219.82M | |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 28.16M | |
| CapitalExpenditure | -6.35M | -4.10M | -7.14M | -9.48M |
| InterestPaidSupplementalData | 5.64M | 5.64M | 5.64M | 9.81M |
| IncomeTaxPaidSupplementalData | 4.58M | 2.01M | 2.21M | 1.31M |
| EndCashPosition | 96.15M | 150.56M | 202.21M | 436.41M |
| BeginningCashPosition | 150.56M | 202.21M | 436.41M | 32.31M |
| EffectOfExchangeRateChanges | -862.00K | 324.00K | -443.00K | -1.43M |
| ChangesInCash | -53.54M | -51.98M | -233.75M | 405.53M |
| FinancingCashFlow | -102.02M | 1.39M | 19.52M | 55.78M |
| CashFlowFromContinuingFinancingActivities | -102.02M | 1.39M | 19.52M | 55.78M |
| NetOtherFinancingCharges | -9.31M | -6.51M | -27.24M | |
| ProceedsFromStockOptionExercised | 7.29M | 7.89M | 19.52M | 25.23M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | -100.00M | 0.00 | 0.00 | 28.16M |
| CommonStockPayments | -100.00M | 0.00 | 0.00 | |
| CommonStockIssuance | 0.00 | 0.00 | 28.16M | |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 29.63M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 29.63M | |
| LongTermDebtPayments | 0.00 | 0.00 | -190.19M | |
| LongTermDebtIssuance | 0.00 | 0.00 | 219.82M | |
| InvestingCashFlow | -18.04M | -153.93M | -316.00M | 14.22M |
| CashFlowFromContinuingInvestingActivities | -18.04M | -153.93M | -316.00M | 14.22M |
| NetInvestmentPurchaseAndSale | -11.68M | -150.82M | -309.86M | 22.70M |
| SaleOfInvestment | 512.38M | 486.10M | 322.45M | 187.63M |
| PurchaseOfInvestment | -524.06M | -636.92M | -632.31M | -164.93M |
| NetIntangiblesPurchaseAndSale | 0.00 | 1.00M | 1.00M | 1.00M |
| SaleOfIntangibles | 0.00 | 1.00M | 1.00M | 1.00M |
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -6.35M | -4.10M | -7.14M | -9.48M |
| PurchaseOfPPE | -6.35M | -4.10M | -7.14M | -9.48M |
| OperatingCashFlow | 66.51M | 100.56M | 62.72M | 335.53M |
| CashFlowFromContinuingOperatingActivities | 66.51M | 100.56M | 62.72M | 335.53M |
| ChangeInWorkingCapital | -16.04M | 61.21M | -298.42M | 172.22M |
| ChangeInOtherWorkingCapital | -349.86M | 311.65M | ||
| ChangeInOtherCurrentLiabilities | -4.39M | -3.63M | -3.12M | -3.23M |
| ChangeInOtherCurrentAssets | -1.19M | 570.00K | 87.00K | 175.00K |
| ChangeInPayablesAndAccruedExpense | 14.93M | 21.76M | -45.21M | 167.81M |
| ChangeInAccruedExpense | 11.03M | 19.81M | -45.90M | 168.57M |
| ChangeInPayable | 3.90M | 1.95M | 691.00K | -767.00K |
| ChangeInAccountPayable | 3.90M | 1.95M | 691.00K | -767.00K |
| ChangeInPrepaidAssets | -3.11M | -4.67M | 147.79M | -194.79M |
| ChangeInInventory | -19.91M | 3.91M | -32.40M | -234.00K |
| ChangeInReceivables | -2.37M | 43.27M | -15.70M | -109.16M |
| OtherNonCashItems | 5.97M | 1.12M | 1.09M | 1.61M |
| StockBasedCompensation | 52.62M | 42.59M | 32.91M | 21.29M |
| AssetImpairmentCharge | 3.14M | 12.31M | 34.29M | 2.59M |
| AmortizationOfSecurities | -14.54M | -16.55M | -4.18M | 470.00K |
| DepreciationAmortizationDepletion | 8.05M | 7.28M | 6.67M | 7.06M |
| DepreciationAndAmortization | 8.05M | 7.28M | 6.67M | 7.06M |
| AmortizationCashFlow | 0.00 | 0.00 | ||
| AmortizationOfIntangibles | 0.00 | 0.00 | ||
| Depreciation | 8.05M | 7.28M | 6.67M | 7.06M |
| OperatingGainsLosses | -1.00M | -2.80M | 53.59M | |
| GainLossOnInvestmentSecurities | -1.80M | 49.35M | ||
| GainLossOnSaleOfPPE | 0.00 | 47.00K | ||
| NetIncomeFromContinuingOperations | 27.31M | -6.39M | 293.16M | 76.71M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for DVAX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|